Skip to content

Managing recurrent VTE over the long term
Session Evaluation

Please complete this activity then scroll to the end and click 'Done'
Thank you for completing this CPD activity. Please complete this evaluation, we will then provide you with a certificate so that you can claim CPD credits.
1.First Name
2.Last Name(Required.)
3.RACGP/ACRRM no(Required.)
4.Contact Email
5.Contact telephone
6.Please rate to what degree your learning needs were met:
7.Please rate how well the following learning outcome was met: Apply coordinated treatment for NVAF and VTE according to the latest guidelines and apply treatment tailored to the individual patient.
8.Please rate how well the following learning outcome was met: Identify thrombosis-associated disease, know when to treat and when to refer for specialist care or to the ED.
9.Please rate how well the following learning outcome was met: Effectively manage the more complex patients with disease, including conditions specific to females with disease.
10.Please rate to what degree this activity is relevant to your practice
11.Has this activity contributed to a systems-based patient safety outcome for your practice?
12.How useful has this meeting been in providing solutions to the current treatment challenges faced by GPs?
13.As a result of the education you have received, do you have increased confidence in managing AF/VTE and related CV disease?
14.Would you recommend this education to a colleague?
Please click 'Done' below to submit your questionnaire
The TGA encourages health professionals to report adverse events to medicines and vaccines. Suspected adverse events reported by health professionals provide important information for the TGA’s safety monitoring program. For further details on reporting a suspected adverse event, please refer to the TGA website: www.tga.gov.au. If you report an adverse event associated with the use of ELIQUIS to the TGA, please provide Pfizer or BMS with a copy.